AXSM
Axsome Therapeutics Inc
173.00$
-0.8%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 85.2% | 85.7% | 84.4% | 84.5% | 85.3% | 85.3% | 82.9% | 83.9% | 84.5% | 85.4% | 85.7% | 86.2% | |
| 69.3% | 65.7% | 60.7% | 57.6% | 58.3% | 55.5% | 50.4% | 47.4% | 48.6% | 46.8% | 42.8% | 42.0% | |
| 69.3% | 65.7% | 60.7% | 57.6% | 58.3% | 55.5% | 50.4% | 47.4% | 48.6% | 46.8% | 42.8% | 42.0% | |
| 13.1% | 16.1% | 18.6% | 22.0% | 22.1% | 25.0% | 27.0% | 31.1% | 29.4% | 32.5% | 35.2% | 36.4% | |
| 1.7% | 2.6% | 2.9% | 2.8% | 2.5% | 2.8% | 2.7% | 2.9% | 3.6% | 4.1% | 4.4% | 5.0% | |
| 1.3% | – | – | – | – | – | – | – | – | – | – | – | |
| 2.0% | 2.0% | 2.2% | 2.2% | 2.1% | 2.1% | 2.0% | 1.9% | 1.8% | 1.7% | 1.7% | 1.6% | |
| 9.1% | 9.1% | 9.5% | 9.1% | 8.6% | 8.2% | 7.6% | 6.8% | 6.3% | 5.9% | 5.5% | 4.9% | |
| 55.1% | 67.5% | 73.6% | 81.2% | 83.5% | 90.0% | 91.1% | 88.6% | 89.0% | 87.2% | 92.4% | 89.1% | |
| 19.1% | 23.6% | 26.4% | 34.0% | 34.9% | 40.5% | 40.9% | 53.5% | 53.8% | 54.9% | 61.5% | 60.5% | |
| 0.1% | 0.2% | 0.3% | 0.5% | 0.5% | 0.6% | 0.4% | 11.3% | 10.9% | 10.6% | 10.3% | 9.3% | |
| 4.8% | 6.9% | 9.9% | 11.2% | 11.4% | 12.7% | 14.4% | 14.3% | 8.1% | 9.5% | 15.0% | 10.4% | |
| 29.5% | 30.3% | 32.7% | 32.7% | 32.1% | 31.8% | 30.4% | 18.4% | 17.6% | 17.1% | 16.5% | 15.5% | |
| 44.9% | 32.5% | 26.4% | 18.8% | 16.5% | 10.0% | 8.9% | 11.4% | 11.0% | 12.8% | 7.6% | 10.9% | |
| -122.6% | -142.0% | -165.6% | -179.4% | -186.6% | -197.5% | -198.1% | -192.3% | -190.9% | -189.3% | -192.1% | -186.7% | |
| 7.8% | 8.0% | 8.7% | 8.7% | 8.6% | 8.5% | 8.2% | 7.7% | 7.5% | 7.3% | 7.2% | 6.8% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.